

What is claimed is:

1. A formulated pharmaceutical composition comprising an addictive substance and at least one nontoxic synthetic substance that blocks the N-methyl-D-aspartate receptor or a major intracellular consequence of N-methyl-D-aspartate receptor activation, and which excludes ketamine, AP-5 and 7-chlorokynureate, the addictive substance being selected from the group consisting of alfentanil, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan and pharmaceutically acceptable salts thereof.
2. The composition of claim 1 in sustained release dosage form.
3. A formulated pharmaceutical composition comprising an addictive substance and at least one nontoxic synthetic substance that blocks the N-methyl-D-aspartate receptor and consists essentially of a morphinan or blocks a major intracellular consequence of N-methyl-D-aspartate receptor activation, the addictive substance being selected from the group consisting of alfentanil, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan and pharmaceutically acceptable salts thereof.
4. A formulated pharmaceutical composition comprising an addictive substance and a non-toxic synthetic substance, the addictive substance being selected from the group consisting of alfentanil, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, isomethadone, levorphanol, methadone, morphine, oxycodone, oxymorphone, pethidine, and pharmaceutically acceptable salts thereof,

*an enhancing agent of a*

*Sub A1  
Paralys  
an opioid  
effect for  
paralysed  
13,485*

*wherein said composition treats  
addiction.*

*will not be  
the actual  
morphine*

the non-toxic synthetic substance being selected from the group consisting of dextromethorphan, dextrorphan, and pharmaceutically acceptable salts thereof.

*Sub  
P1  
Cont*

5. A formulated pharmaceutical composition comprising an addictive substance and a non-toxic synthetic substance, the addictive substance being selected from the group consisting of alfentanil, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, isomethadone, levorphanol, morphine, oxycodone, oxymorphone, pethidine, and pharmaceutically acceptable salts thereof, the non-toxic synthetic substance being a blocker of the N-methyl-D-aspartate receptor and consisting essentially of morphinans.
6. A composition according to claims 1, 3, 4 or 5 wherein the addictive substance is selected from the group consisting of alfentanil, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, isomethadone, methadone, morphine, oxycodone, oxymorphone, pethidine, and pharmaceutically acceptable salts thereof.
7. A composition according to claims 1, 3, 4 or 5 wherein the addictive substance is selected from the group consisting of alfentanil, codeine, dihydrocodeine, fentanyl, isomethadone, methadone, pethidine, and pharmaceutically acceptable salts thereof.
8. A composition according to claims 1, 3, 4 or 5 wherein the addictive substance is selected from the group consisting of codeine, methadone, and pharmaceutically acceptable salts thereof.
9. A composition according to claims 1, 3, 4 or 5 wherein the addictive substance includes morphine or a pharmaceutically acceptable salt thereof.
10. A composition according to claims 1, 3, 4 or 5 wherein the addictive substance includes oxycodone or a pharmaceutically acceptable salt thereof.
11. A composition according to claims 1, 3, 4 or 5 wherein the addictive substance includes hydrocodone or a pharmaceutically acceptable salt thereof.

12. A composition according to claims 1, 3, 4 or 5 wherein the  
addictive substance includes oxymorphone or a  
pharmaceutically acceptable salt thereof.
13. A composition according to claim 1, 3, 4 or 5 wherein the  
addictive substance includes hydromorphone or a  
pharmaceutically acceptable salt thereof.
14. A composition according to claims 1, 3, 4 or 5, in oral  
dosage form.
15. A composition according to claims 3, 4 or 5, in sustained  
release dosage form.
16. A composition according to claims 1, 3, 4 or 5, in oral  
dosage and sustained release dosage form.